Introduction {#s1}
============

Functionalized nanoparticles (NPs) with various linkers and functional groups have been developed as carriers for drugs,^[@R1]-[@R3]^ genes.^[@R4],[@R5]^ They can be further decorated with targeting agents such as antibodies (Abs)^[@R6]-[@R8]^ and aptamers (Aps)^[@R9],[@R10]^ used for targeted imaging and therapy -- an approach the so-called diapeutics/theranostics. To improve the efficacy of targeted diagnosis and therapy, surface modification of these NPs with specific linkers and chelators seems to be necessary steps in development of these NSs,^[@R11]^ upon which while these modified NPs may potentially influence the pathways of personalized medicine.^[@R12],[@R13]^ Besides, *in vitro* evaluations for biological activities and medical imaging techniques are the foundation of both treatment and diagnosis in various diseases. The ultimate aim is to cure formidable diseases (e.g., malignancies) or palliate them non-invasively without surgical interferences with least side effects.^[@R14],[@R15]^ Among various types of molecular imaging agents, NP-based molecular probes, in particular magnetic NPs (MNPs) and gold NPs (GNPs), offer significant potential for effective target-guided imaging and therapy.^[@R16],[@R17]^ The physicochemical properties of various NPs (e.g., size, morphology, surface potential and multivalency) and their unique optical properties have been widely exploited for development of advanced DDSs that can offer seamless multimodality for targeted imaging and therapy of different tumors.^[@R18]-[@R25]^

In fact, molecular imaging and any improvements of molecular probes towards targeted guided visualization of intracellular events in living body without any disruption at molecular and cellular scale, can be remarkably useful step not only for better understanding of diseases' mechanisms but also for advancement of targeted delivery of drugs/genes to the designated cells/tissue.^[@R26]^ For enhancement of particular treatment approaches and evaluating efficiency of therapy, at the initial stages of diseases, the exact information about tumor anatomical site \[the so-called tumor microenvironment (TME)\] plays a significant role in development of such advanced NSs.^[@R27]^ Hence, different imaging techniques with notable ability in scanning micro-quantitative molecular events are capable of providing robust tools for discovery of signaling pathways -- necessary for precise clinical diagnostics and effective treatment using theranostics/diapeutics.^[@R11],[@R28],[@R29]^ Nuclear imaging of diseases, cancers included, with radiolabeled compounds has been well-established in research and practice for decades. While various advanced materials have been used for development of NSs, a number of powerful imaging techniques have also been employed for NP/NS-based imaging including single photon emission computed tomography (SPECT) and positron emission tomography (PET). These imaging modalities are the most conventional imaging methods that depend on the radionuclides properties.^[@R30]^ In the current study, we will provide important insights upon the radiolabeled NPs/NSs and will discuss their biomedical/pharmaceutical applications in relation with the imaging techniques used.

Imaging techniques used for diagnosis {#s2}
=====================================

Various imaging tools have been employed for diagnosis of formable diseases such as solid tumors. [Fig. 1](#F1){ref-type="fig"} represents the imaging techniques for diagnosis of the diseases.
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SPECT {#s2-1}
-----

SPECT is an interesting imaging technique with distinctive feature, which can be applied for imaging of various endogenous ligands using different radiolabeled isotopes. Possibility to image the emerging phenomena at cellular/molecular level (e.g., cell division and metabolic activities of cell), onset/progression of infection or inflammation and delivery of labeled therapeutics (the so-called radiopharmaceuticals) has been proved by SPECT, in large part because of the long half-life, slow tissue diffusion and slow blood clearance of SPECT-related radiopharmaceuticals.^[@R31],[@R32]^ In addition, SPECT has significant potential in visualization of different functions simultaneously by probing various molecular processes at the same time via detecting different emission energies which has been radiated by radioisotopes.^[@R33]^

PET {#s2-2}
---

PET is another valuable technology with the great diagnosis ability of *in vivo* abnormalities at cellular/molecular level providing quantitative imaging.^[@R34]-[@R36]^ In this system, high speciﬁc activity of the radiopharmaceuticals has been used to obtain images with high quality which provides diagnosis with high sensitivity and confidence, considering the fact that a minimum dosage of radiopharmaceuticals and radiation is safe enough to act in biologic systems without being harmful.^[@R37],[@R38]^ PET and hybrid imaging techniques such as PET/ magnetic resonance imaging (MRI) have been advanced with NP-based probes for multimodal applications.^[@R39]^

MRI {#s2-3}
---

MRI, as a noninvasive and non-ionization imaging method, has remarkable potential for the monitoring of the responses to therapies and tumor progression. MRI spots water molecules at various tissues via magnetic fields.^[@R14],[@R40]^ Different contrast agents have been used to support adaption of this diagnostic technique.^[@R41],[@R42]^

Optical imaging systems {#s2-4}
-----------------------

Optical imaging systems are another types of dual-modality methods which have been used in the clinical practice, in large part due to their significant complementary imaging features.^[@R43]^ Although valuable images can be obtained by available imaging techniques, most of these modalities have limitations to provide sufficient sensitivity and resolution. Hence, appropriate labeling procedures are necessary for development of sensitive probes with ability for recognition by two imaging systems, which can be clinically more valuable to integrate the strengths of the both imaging modalities.^[@R44],[@R45]^

Hybrid imaging systems {#s2-5}
----------------------

In comparison with single modality operating system, complementary results can be obtained by multimodality imaging which combines functional imaging techniques (e.g., PET, SPECT) with anatomically three-dimensional (3D) imaging modalities (e.g., MRI, CT).^[@R46],[@R47]^ PET/CT developed as a remarkable dual-modality system which has been used in clinical practice whereas patients may exposed a considerable quantity of ionizing radiation by CT (i.e., X-ray computed tomography) imaging.^[@R48],[@R49]^ Compared to the CT, the MRI modality has the potential to produce images of soft tissues with better resolution and minimum dangerous emission exposure to patients. The PET/MRI imaging modality, the visualization technique has been used to improve the medical applications, particularly in detection of cancer cells, stem cell therapy and neurological investigations by presenting enhanced soft-tissue contrast and more functional information with lower radiation exposure.^[@R50]^ Any contrast agent applied for such imaging should be safe and non-toxic for the *in vivo* applications.

Emergence of nano-imaging techniques {#s2-6}
------------------------------------

Diagnostic and targeted affinity molecular imaging can be obtained by nanoscaled advanced materials, including: quantum dots (QDs),^[@R24],[@R51]^ solid lipid nanoparticles (SLNs),^[@R5],[@R52]^ liposomes,^[@R33],[@R53]^ metallic NPs, dendrimeric and polymeric NPs,^[@R54]^ carbon nanotubes,^[@R55]^ micelles,^[@R56],[@R57]^ and iodinated NPs.^[@R58],[@R59]^ Biologically, appropriate synchronic molecular reactions, such as sufficient adhesion strength with cell, are essential for NPs/NSs intended for overcoming hydrodynamic forces persuaded via blood circulation and remaining on cell surface in the living organisms.^[@R60]^ NPs with ability to target various ligands (e.g., peptides, proteins, Abs, Aps and nucleic acids) are important compounds for the evaluation of combined imaging probes (e.g., PET/MRI and PET/CT) because they have the capability to increase the signal to noise ratio in imaging by conjugating with fluorophores, radionuclides and other reporter molecules.^[@R61],[@R62]^ Based on these facts, radiolabeled NPs play an important role in molecular imaging that will be further discussed in the following sections of the article. [Fig. 2](#F2){ref-type="fig"} represents the imaging techniques for diagnosis of the diseases.
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Imaging with radiolabeled NPs {#s3}
=============================

The specific potential of NPs in imaging has gained much attention as an alternative approach for cancer diagnosis and therapy in the last two decades. These nanoscaled theranostics are seamless NSs that are able to target the diseased cells and provide on-demand imaging and treatment potentials. Comprehensive physiologic data could be obtained by these NSs in both *in vitro* and *in vivo* applications, in large part because of their unique features such as size, morphology and photoacoustic properties. For instance, GNPs, semiconducting metals and iron oxides based NPs have successfully been used in development of theranostics.^[@R64],[@R65]^ In fact, superior signal sensitivity, enhanced spatial resolution and multiple possibilities of modification along with reliable information about the molecular and cellular levels could be achieved by application of these nanoprobes in various imaging methods such as fluorescence imaging, near infra-red (NIR), CT, PET, SPECT and MRI.^[@R66]^ In one study, for example, technetium-99m-labeled GNPs (20 nm) were conjugated Hydrazinonicotinamide-Gly-Gly-Cys-NH~2~ (HYNIC-GGC)/mannose and tested in as a potential radiopharmaceutical for detection of the sentinel lymph nodes in rats using a micro-SPECT/CT system. These radiopharmaceuticals showed high radiochemical purity (\>95%) and provided capability of specific detection of mannose receptors in rat liver tissue with 99% radioactivity levels in the popliteal and inguinal lymph nodes. As a result, these NSs were proposed as a target-specific radionanoconjugates for detection of diseased lymph nodes.

Radiolabeled MNPs {#s4}
=================

Recent developments in synthesis, physicochemical characterization and molecular recognition of MNPs for molecular imaging and therapeutic applications of the MNPs make them as sound theranostics for targeted delivery of drugs and genes, in large part due to their toxicological and metabolic reactions are predictable.^[@R2],[@R67]-[@R70]^ MNPs with distinctive features (e.g., high surface, quantum specificities, and small size) are significantly useful for optical and magnetic imaging. In addition, these NSs prevent from accumulation even in intense magnetic platform and have favorable capability to use as magnetic fluid preparation.^[@R71]^ MNPs, especially as small or ultra-small superparamagnetic iron oxide NPs (SPIONs and USPIONs, respectively) offer unique external tuning that is very important for biomedical applications and improvement of thermal therapy with low toxicity.^[@R72],[@R73]^ Effective surface conjugation of biocompatible MNPs with Abs, Aps, proteins and enzymes offers the possibility of using these NPs in specific targeting of diseased tissues such as tumors.^[@R74],[@R75]^ It should be pointed out that the SPIONs with hydrophobic surface can be accumulated within the healthy liver tissue as a consequence of their rapid absorption by macrophages and Kuppfer cells of reticuloendothelial system (RES). Minimized RES assimilation is achieved by conjugating of SPIONs with different biomaterials and hydrophilic polymers (e.g., PEG) that improves their blood half-life and enhanced permeability and retention (EPR) effect and consequently particular accumulation in tumor cell may occur.^[@R57],[@R76]^

PET or SPECT imaging with high quantification is achieved by radio labeling SPIONs with nuclear medicine isotopes as imaging agent.^[@R77],[@R78]^ Further, high relaxivity in MRI imaging with higher safety than gadolinium based MRI allows SPIONs to be applied as contrast enhancement agents in MRI.^[@R79]^

MNPs for PET imaging {#s4-0-1}
--------------------

PET as a nuclear imaging method provides the opportunity for monitoring different biological and/or physiological phenomena in living systems through administration of radiolabeled probes.^[@R80]^ To date, various types of magnetic NPs have been functionalized with suitable radionuclides for PET imaging.^[@R81]^ A cyclotron like^18^F, ^11^C, ^64^Cu, ^124^I, ^86^Y, ^15^O and ^13^N, or a generator like ^68^Ga as positron-emitting radioisotopes have been used in PET imaging technique to monitor emitted γ rays.

Peptide receptors have potential to overexpress in human cancer cells and could be used as molecular targets for radiolabeled peptides for early detection of tumor angiogenesis. Atrial natriuretic peptide with anticancer feature interacts with cell surface natriuretic peptide receptor A and natriuretic peptide clearance receptor, which expressed in tumor angiogenesis and consequently could be used in therapy and PET imaging. PET imaging of C-type atrial natriuretic factor (CANF) peptide conjugated with polymeric NPs as amphiphilic comb-like NPs (^64^Cu-CANF-Comb) has the potential to apply as a prognostic marker to target the prostate cancer cells.^[@R82]^ Given that the tissue macrophages are very important for standard physiological and disease circumstances because of their wide distribution, a number of investigations have been conducted to analyze the macrophages functions in cancer.^[@R83]-[@R85]^ In anticipation that coordinated NPs are able to prolong the circulation times to assimilate into macrophages, NP-based PET/CT and PET/MRI have been developed.^[@R85]-[@R87]^ In a study, Zirconium-89 (^89^Zr) with long half-life has been opted as PET isotopes for imaging. Quantitation of tumor-associated macrophages have been accomplished by injection of radiolabeled dextran-coated MNPs that have significant macrophage avidity.^[@R88]^ [Fig. 3](#F3){ref-type="fig"} illustrates the *in vivo* micro-images of PET and CT and multimodal NPs used for PET imaging.
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Given that the tumor-associated macrophages (TAMs) are extremely important in solid tumors with great diagnostic and prognostic as well as targeting values,^[@R89]^ in a study, ^89^Zr-labeled high-density lipoprotein (HDL) NPs-facilitated PET imaging has been performed for detection of TAMs in orthotopic mouse model of breast cancer. HDL NPs were formulated using phospholipids and apolipoprotein A-I and conjugated with ^89^Zr complexed with deferoxamine. Intravenous administration of these NSs resulted in profound tumor radioactivity 24 h after injection, which was revalidated with histologic analysis showing high colocalization in the TAM-rich tumor sections. Based on such findings, the researchers recommended these NSs for quantitative detection of TAMs as noninvasive monitoring strategy in solid tumors.^[@R85]^

MNPs for SPECT imaging {#s4-0-2}
----------------------

MNP-based targeting strategy have been considered as remarkable method for the controlled delivery of advanced DDSs and multimodal theranostics, which can be armed with various radiopharmaceuticals such as SPECT-radioisotopes, as listed in [Table 1](#T1){ref-type="table"}. MNPs decorated with radioisotopes and homing devices and loaded with cytotoxic agents can simultaneously target the aberrant cells and release anticancer drug molecules into tumor sites in cancer treatment and diagnosis. MNPs have been conjugated with technetium-99m (^99m^Tc) and used for *in vitro* and *in vivo* studies. I has been reported that the ^99m^Tc-armed MNPs could be a base for the targeted delivery and imaging techniques by radiopharmaceuticals.^[@R88]^

###### Selection of radioisotopes for SPECT imaging and/or therapy

  --------------------------- --------------- ---------------------------------------- ----------------------------------------------
  **SPECT-isotopes**          **Half-life**   **β** ^---^ **Energy average \[keV\]**   **γ-Energy**
  ^99m^Tc‏ (Technetium-99m)   6.02 h          \-                                       141 keV (89 %)
  ^111^In (Indium-111)        2.80 d          \-                                       171 keV (91 %), 245 (94 %)
  ^67^Ga (Gallium-67)         3.26 d          \-                                       93 (39 %), 185 (21 %), 300 (17 %), 394 (5 %)
  ^123^I (Iodine-123)         13.22 h         \-                                       159 (83 %)
  ^131^I (Iodine-131)         8.03 d          182 (100 %)                              365 (82 %)
  ^186^Re (Rhenium-186)       3.72 d          347 (93 %)                               137 (9.5 %)
  ^188^Re (Rhenium-188)       17.0 h          763 (100 %)                              155 (16 %)
  ^67^Cu (Copper-67)          2.58 d          141 (100 %)                              185 (49 %)
  ^177^Lu (Lutetium-177)      6.65 d          134 (100 %)                              113 (10 %), 208 (10 %)
  --------------------------- --------------- ---------------------------------------- ----------------------------------------------

MNPs have been used for the detection of sentinel lymph node biopsy in breast cancer.^[@R90]^ Application of dipicolylamine alendronate magnetic nanoparticle tracer for localization of non-palpable breast lesions using a handheld magnetometer was developed as a clinical indication. This NS was prepared by radiolabeling of SPIONs with ^99m^Tc and alendronate after coating with biocompatible carboxydextran to prevent agglomeration and immune clearance. The MNPs-based NS demonstrated positive localizations in phantom models with predictable performance patterns.^[@R56]^

MNPs as dual modality for imaging and targeted therapy {#s4-0-3}
------------------------------------------------------

In addition to imaging techniques (e.g., MRI, PET and CT), combination of molecular imaging modalities have been developed and shown to provide synergistic advantages in early-stage diagnosis of malignancies with more detailed information to clinicians in comparison with any single imaging modalities. Overall, MRI is considered as a noninvasive imaging strategy with wide applications in clinic, in large part because of plausibility to modify SPIONs with different biomolecules and decorate them with specific agents ([Fig. 3](#F3){ref-type="fig"}). In addition to being suitable tissue contrast agent, they can be used for monitoring of tumor progression, while providing possibility for accumulation of NPs in tumor side and on-demand liberation of anticancer drug molecules using an external stimuli. All these feature are due to large surface of SIONPs, and possibility for surface functionalization make them unique NSs.^[@R91]^ It should be stated that the dual- modality imaging NPs can be employed through either passive or active targeting mechanism. The passive targeting is the accumulation of drug at a tissue with physicochemical or pharmacological aspects through the EPR effect, while the uptake of NPs by the kupffer cells of the liver or RES can affect the end point aim of the treatment. In the active targeting mechanism, NPs are armed with a homing agent to specifically target the designated diseased cells. In fact, the delivery of NPs to the metastatic solid tumors demands specific and active targeting approach using Abs/Aps to target the cancer antigens.^[@R92]^ In the following context, we will discuss some of these approaches.

*In vivo* integrity of stabilized SPIONs in the systemic circulation directed researchers to use them in nuclear medical imaging for dual modality imaging purposes. Radiolabeled MNPs like MRI contrast agents have longer blood shelf life, superior sensitivity, fewer adverse effect, and larger numbers of radionuclides in comparison with gadolinium-based pharmaceuticals. Designing MNPs with various physicochemical properties make development of multimeric NSs possible, which can be further modified with different moieties. MNPs, as robust core, offer significant plausibility for surface modification while showing excellent optical properties, which make them one of the best candidates for dual molecular imaging and targeted therapy.^[@R93]^ Development of Cu(II)-labeled MNPs covered by porous silica shell (SPION\@SiO~2~) have been considered as PET/MRI contrast agent, which has been tested as stem cells labeling agent. This NS displayed great biocompatibility, relaxivity, low toxicity in long-term *in vivo* uses. These SIPON-based NS was successfully used for the detection and tracking of stem cells, which was also reported as robust technique for the diagnosis of anomalous cells.^[@R94]^ In a study, MNPs were modified to display greater degrees of hydrophilicity through deposition of Al(OH)~3~ layer, which resulted in production of a bimodal contrast agents to be used in PET/MRI imaging after radiolabeling with copper-64 (^64^Cu). High affinity of aluminum hydroxide with fluoride anions and bisphosphonate groups (^64^Cu-bisphosphonate) offers a simple method of radiolabeling and functionalization with high biocompatibility. Small size, controllable surface potential, superior colloidal stability and fine transverse relaxivity were the properties of this NS as a theranostic probe.^[@R95]^

Recently, MNPs were modified and with PEG decorated with ^125^I radionuclide and 3H11 Ab, which were examined for detection of xenografted tumors. As a dual-modality molecular probe, this MNP-based NS was successfully used for the MRI/SPECT anatomical and functional images.^[@R96]^ In another study, PEGylated MNPs were stabilized with oleic acid and phospholipids to improve its aqueous dispersibility. To engineer MRI/SPECT/PET three-modality imaging probe, they were radiolabeled with Indium-111 (^111^In), ^59^Fe (to label the iron oxide core) and ^[@R14]^C to label the oleic acid used in shell. The bio-distribution studies showed that despite detection of ^111^In in reticuloendothelial organs, ^59^Fe analysis showed a greater level than^111^In in liver and spleen, while analysis of ^[@R14]^C demonstrated lower levels.^[@R97]^

As another case, PEGylated SPION probe was developed for dual modality PET/MRI imaging by modification of MNPs with phospholipids and ^64^Cu radioisotope. The ^64^Cu-SPION probes appeared to offer great imaging possibility in detection of atherosclerosis and cancers, showing desirable stability in mouse serum.^[@R98]^ A multifunctional and water-soluble PEGylated SIPON was recently developed and used for PET/MRI dual modality imaging and specific delivery of doxorubicin (DOX) through targeting tumor-associated marker, integrin avb3. The NS offered great PET imaging potential studied through biodistribution and higher accumulation in tumor sites, and also resulted in an enhanced sensitivity in terms of MRI detection while specifically delivering the DOX molecules to the anomalous tumor cells.^[@R99]^

PET/MRI dual-modality molecular probe by speciﬁc chelator-free radiolabeling approach and PEGylated SPION with ^69^Ge (^69^Ge-SPION\@PEG) was fabricated by Chakravarty *et al*. PEG modification enhanced the *in vivo* and *in vitro* stability of the NS in the serum, while notable uptake of NPs in the liver and spleen was observed after intravenous injection in normal BALB/c mice analyzed by PET imaging technique. Additionally, the liver uptake of ^69^Ge-SPION\@PEG was verified by *in vivo* MRI. Noninvasive PET/MRI dual-modality sentinel lymph nodes mapping was also investigated by PET and MRI scans separately that showed accumulation of ^69^Ge-SPION\@PEG in the popliteal lymph node. Therefore, this chelator-free method was proposed as proper strategy for production of multifunctional theranostics.^[@R100]^

Thorek *et al*. established a multimodal NS based on ^89^Zr-ferumoxytol MNPs, and examined its potential in noninvasive mapping of lymph nodes by PET/MRI dual-imaging technique. The desferrioxamine chelate (DFO) was linked to ferumoxytol with a valuable toxicity outline to produce the ^89^Zr-DFO-labelled ferumoxytol (^89^Zr-ferumoxytol). The engineered NS was tested through PET/CT, MRI and PET/CT/MRI imaging modalities, which demonstrated high sensitivity and resolution delineation of the nodes following an axillary drainage in naive mice, healthy and prostates tumor suffering mice. Upon such findings, it seems that the engineered NS can be translated to clinical applications towards lymph nodes imaging in deep tissues.^[@R101]^

A MNP-based multimeric NS has recently been developed by Tsiapa *et al*. In this study, MNPs were modified with aminosilane and conjugated with cyclic Arg-Gly-Asp-D-Phe-Lys (cRGDfK) and an ornithine-modified peptide (cRGDfK-Orn3-CGG), which was labeled with ^99m^Tc. Given that cRGDfK is RGD derivate, ^99m^Tc-cRGDfK-Orn3-CGG nanosystem was examined as a targeted tumor molecular imaging and thermal therapy agent in both normal and alphanubeta3-positive tumor (U87MG glioblastoma) bearing mice. It was found the NS was able to showed high affinity to the integrin αvβ3 receptor with absorbing specificity in several tumors cells. A hyperthermia session was applied *in vivo* in a U87MG glioblastoma tumor bearing animal model treated with the NS, showing their accumulation and marked impacts in tumor side. This NS with high specific targeting potential was proposed as a suitable agent for dual modality SPECT/MRI imaging through targeting integrin αvβ3.^[@R102]^

For targeted imaging of cancer, Zolata *et al*. developed a NS based on minosilane-PEG coated SPIONs armed with trastuzumab (an Ab specific to HER2) and loaded with DOX, which was radiolabeled with ^111^In radionuclide. SPECT/MRI analyses showed that the NS was able to accumulate within the TME through passive targeting mechanism (EPR effect) and target the HER2-possitive cancer cells though active targeting mechanism. SPECT/MRI imaging and therapeutic evaluation in HER2-possitive BALB/c mice bearing breast tumor indicated that the functionalized NS maintained its magnetic properties and ability to target HER2 over expressing in tumors, as a result they could be applied as dual-modality imaging agent. The suitable coating and active targeting by trastuzumab together with ^111^In-based PET imaging and SPION-based MRI imaging made the NS as a stable and long-circulating robust agent, while the accumulation of NPs in the TME and controlled release of DOX molecules in the tumor site make it a vigorous anticancer agent.^[@R90]^

Bisphosphonates (BPs) are well-known drugs in the osteoporosis and oncology because they could bind avidly to the surface of metabolically active bone. Conjugation of bisphosphonates to the surface of SPIONs and decoration with radionuclides make them suitable for SPECT/PET-MRI imaging. In a study, this NS systems was conjugated with ^99m^Tc-dipicolylamine-alendronate and used as dual-modal imaging agent in comparison with other agents such as Endorem®/Feridex® used as MRI contrast agent. Co-localization of ^99m^Tc and Endorem® in the RES system confirmed by *in vivo* MRI and SPECT-CT imaging demonstrated that the engineered bimodal imaging nanoprobe displayed high stability in the blood with substantial sensitivity.^[@R103]^ Radiolabeled bisphosphonate-USPIONs armed with ^99m^Tc-DTPA have also been used for *in vivo* tracking of the NPs by SPECT/PET/MRI imaging. The engineered NS demonstrated a great sensitivity and quantification properties in mice treated with the NS, showing strong T1-effect which is related with longer blood circulation and enhanced the signal.^[@R104]^

Further, the vulnerable atherosclerosis plaque rupture-induced acute obstructive vascular diseases are attributed to relatively high morbidity and mortality worldwide, hence accurate diagnosis and detection of the atherosclerosis onset and/or progression seems to be essential. To tackle this, in a study, USPIONs were decorated with diethylenetriaminepentaacetate acid (DTPA) and PEG and labeled with ^99m^Tc to produce a multimodal NS (^99m^Tc−DTPA−USPION−Annexin V) that is tested by some *in vitro* examinations and SPECT/MRI imaging. Given that Annexin V is able to target the apoptotic macrophages abundant in vulnerable plaques, the accumulation of the NSs in the plaques was confirmed by both *in vitro* and *in vivo* experiments.^[@R105]^

Fluorescence quenching ability of optical dyes and QDs has also been exploited for development of a new class of MNPs. An enzyme responsive SPION-based NSs grafted with optical dyes have also good potential as imaging agents that could be activated during imaging process. Such system as a MRI and NIRF optical imaging probe has been engineered and used for cancer diagnosing based on ﬂuorescence quenching ability of iron oxide.^[@R106]^ Similarly, a hybrid multimeric NS based on MNP has been engineered (^64^Cu-NOTA-Au-MNP-affibody nanoprobe) by Yang *et al*. It was used for targeted cancer imaging in the human EGFR expressing cells and tumors, and resulted in high quality micoimages obtained by PET/Optical/ MRI imaging techniques. *In vivo* and *in vitro* studies demonstrated that the affibody-targeted Au-MNPs system is a robust nanoprobe that can be further modified with targeting molecules (Abs/Aps specific to cancer antigens such as EGFR) and PET imaging reporters (e.g., ^64^Cu) and used for target-guided diagnosis.^[@R16]^

To establish a nanoprobe for PET and MRI imaging, Pombo-Garcia *et al*. reported on development of a bimodal USPIONs probe coated with octylamine-modified polyacrylic acid (OPA) as an amphiphilic polymer with the subsequent conjugation with a new amino pendant-bearing derivative of the ^64^Cu (II) chelator, N-(4-aminophenyl)-2-\[4, 7-bis(2-pyridylmethyl)-1,4,7-triazacyclononan-1-yl\]-acetamide (amino-dmptacn). It should be noted that the OPA make MNPs to be water-dispersible with high colloidal stability, which also provides a good potential for further decoration of NPs with different entities. The biocompatibility and cellular uptake of the functionalized USPIONs were evaluated in normal and tumor cell lines. Results showed a cell type and time-dependent internalization of the OPA-USPIONs, and substantial stability in the serum, which indicated that the NS may be considered as a bimodal PET-MRI tumor imaging agent.^[@R107]^

Another radionuclide-labeled NS was formulated based on ^64^Cu (II) silica-coated MNPs and tested for its potential to serve as an imaging nanoprobe for bimodal recognition of tumors by MRI and PET. Following the covalently binding of MNPs to the synthesized siloxane derivatives of 1,4-bis(2-pyridylmethyl)-1,4,7-triazacyclononane (dmptacn), 1,4,8,11-tetraazacyclotetradecane (cyclam) or 1,4,7,10-tetraazacyclododecane (cyclen), they were factionalized with ^64^Cu^2+^. The macrocycle-containing NPs with mean hydrodynamic diameter, aggregated in buffered aqueous solution with the radioactivity persistence in the rat plasma. Nanoparticle tracking analysis of cyclam-functionalized NPs confirmed the radio copper complexes high stability, where the dmptacn-functionalized NPs performed the highest resistance to metal ion leakage that provides a robust nanoprobe for multimodal cancer dual (MRI/PET) imaging and hyperthermia treatment of cancer.^[@R108]^

Radiolabeled GNPs {#s4-5}
=================

An ideal physicochemical properties of GNPs (e.g., large surface, tunable size, low reactivity, high stability and biocompatibility, and low reactivity) together with their high binding affinity to selected organic molecules with thiol terminal groups and remarkable photoacoustic features provide them significant capabilities for biomedical applications. GNPs have been studied for imaging and therapeutic applications in the past decades. Different forms gold nanostructures (e.g., NPs, nanospheres, nanocages, nanorods and nanoshells) have been pre-clinically investigated for molecular imaging. Active targeting of the diseased cells by these agents can be achieved by modification of their surfaces with various ligands specific to cancer-associated antigens ([Fig. 3](#F3){ref-type="fig"}). The targeted GNPs are able to target the diseased cells and markedly accumulate in the tumor cells/tissue.^[@R109]^ In addition, gold nanoshells (GNSh), because of their distinctive properties (e.g., size, composition, physical and optical specificity), are significant nanostructures for photothermal ablation of cancer cells.^[@R110]^ Biologically, the gold-based NSs are considered as bio-inert, nontoxic and easily modifiable agents, which can be used through passive and/or active targeting mechanisms for both *in vitro* and *in vivo* applications.

GNPs for PET imaging {#s4-0-4}
--------------------

A noninvasive PET imaging with high sensitivity in real time, provides quantitative imaging of the NPs assimilation at the target tissue.^[@R38]^ GNP-based PET imaging is a robust approach for the detection of diseased cells. While the pharmacokinetics (PK) and biodistribution of the gold-based NSs can be monitored by PET, these nanostructures (in particular GNSh-based nanoprobes) may be activated for the concurrent photothermal ablation of cancerous cells even against the relatively small metastatic cells. PET/CT imaging of ^64^Cu-GNSh was shown to offer a reliable labeling efficiency with high stability.^[@R111]^ These NSs were reported to largely taken up by the diseased cells *in vitro* and *in vivo,* as shown in the live nude rats bearing head and neck squamous cell carcinoma xenografts after intravenous administration. Specific localization was determined using CT imaging, at which point these NSs appear to offer efficient potentials for imaging and on-demand photothermal ablation of cancer cells.^[@R111]^

In a study, GNPs (5 nm in diameter) were decorated with cetuximab (a speciﬁc Ab against EGFR) functionalized with chelating agent desferal and further labeled with ^89^Zr to provide a PET imaging nanoprobe. The GNPs--PPAA--cetuximab--^89^Zr provided good PET imaging potential in mice model that was suggested as a significant alternative approach for surgery or radiation at malignant tumors.^[@R112]^ In another interesting study, GNPs were labeled with ^64^Cu and examined for PET imaging in an EMT-6 mouse breast cancer model. The engineered ^64^Cu-GNPs were further PEGylated to improve its stability in serum and show long blood circulation *in vivo.* Once used in animal model, the NSs showed great applicability in both PET imaging and autoradiography. This strategy developed the potential of ^64^Cu-GNPs for additional oncological, preclinical and translational PET imaging application.^[@R113]^ Similarly, PEGylated GNP-^64^Cu was used as a radiotracer for the PET imagingof *in vivo* biodistribution of adoptive transfer of primary T cells. On the ground that CD19-specific CAR-positive T cells have important clinical applications in patients with B-cell malignancies, using Sleeping Beauty (SB) transposon system, the primary isolated T cells were genetically modified to co-express a chimeric antigen receptor (CAR) specific for CD19 using CAR transposon and the Firefly luciferase (ffLuc) using ffLuc transposon, which have been done by means of electro-transfer of DNA plasmids. To track the T cells *in vivo*, the CD19-specific CAR-positive T cells were loaded with the PEGylated GNP-^64^Cu by electroporation imaged by µPET/CT technique. The results revealed the PEGylated GNP-^64^Cu have great potential as a radiotracer in PET/CT imaging of T cells *in vivo*, which could be a useful method in immunotherapy of cancer.^[@R114]^

In a study, to develop a targeted dual-modality PET/CT imaging nanoprobe, PEGylated hollow GNPs was conjugated with cyclic RGD peptide (cRGDfK) and labeled with ^64^Cu (RGD-PEG-hGMP-^64^Cu). The engineered NS was tested for the *in vivo* distribution and quantitative analysis of intratumor accumulation. To this end, VX2 tumor-bearing rabbits were subjected to PET/CT imaging after hepatic intra-arterial (IA) and intravenous (IV) administration of the nanoprobe. It was found that the NS was able to significantly target the integrin αvβ3 receptors expressing cells, resulting in uptake of the RGD-PEG-hGMP-^64^Cu nanoprobe by the diseased cells. Once decorated with lipiodol (ethiodized oil), the RGD-PEG-hGMP-^64^Cu nanoprobe showed considerably higher tumor uptake, maximizing the PET/CT imaging detection potential.^[@R115]^

The ^68^Ga-RGD-PEG GNP is a dual-modality PET/MRI imaging nanoprobe that has been developed by radiolabeling of GNPd with ^68^Ga. The targeted imaging potential of the nanoprobe has been evaluated by the *in vitro* imaging of cancer cells through targeting the integrin aνb3 receptor-positive U87MG cancer cells, the *ex vivo* biodistribution studies, and also the *in vivo* PET and MRI imaging in U87MG tumor-bearing SCID mice. The engineered NSs exhibited high radiolabeling yield, high stability, specific recognition of U87MG glioma cells and enhanced *ex vivo* biodistribution ratio from tumor to muscle where the PET and MRI *in vivo* images supported the *ex vivo* results.^[@R116]^

Recently, ^64^Cu alloyed gold nanoclusters (GNCs) were prepared through a one-step synthesis method (^64^Cu-GNC-PEG). For the PK evaluations, the renal clearance and systemic clearance were studied using PET imaging in a mouse prostate cancer model. The ^64^Cu-GNC-PEG NSs were obtained by chelator-free radiolabeling with precise incorporation of ^64^Cu into the GNCs structure. The high specific activity guaranteed minimum dosage administration for sensitive and precise *in vivo* PET/CT tumor localization. Optimal biodistribution as well as significant renal and hepatobiliary excretion present a broader range of biomedical applications of obtained radio-metal alloyed NS that may be used for pre-clinical and translational researches.^[@R117]^

GNPs for SPECT imaging {#s4-1}
----------------------

Of various golg-based NSs, ^131^I-labeled immuno-GNPs (^131^I-C225-GNP-PEG) have been developed as a theranostic agent by labeling of cetuximab grafted GNPs with ^131^I. The NS was examined in EGFR-possitive human lung cancer A549 cells. The engineered ^131^I-C225-GNPs-PEG showed particular uptake in A549 cells and significantly reduced the viability of cells. Micro SPECT/CT imaging clearly demonstrated valuable radioactivity maintenance in tumor tissue after intra-venous administration of ^123^I-C225-GNPs-PEG in tumor-bearing mice. This radio immuno-gold theranostic agent showed anti-proliferation specificity against EGFR over-expressing cancer cells and provided clear tumor imaging in an A549 human lung carcinoma-xenograft animal model.^[@R65]^ Direct labeling for tracking GNPs by conjugation of GNPs with ^[@R111]^In radionuclide provided high activities and excellent stability within the biological system. Molecular targeting of the integrin avß3 receptor was obtained through *in vivo* and *in vitro* imaging of athymic nude mice, human melanoma and glioblastoma by modification of the engineered NPs with RGD-based ligands.^[@R118]^

Conjugation of ^99^Tc labeled GNPs to HYNIC-GGC peptide/mannose was performed to investigate the potential of radiopharmaceutical for the detection sentinel lymph node. The accurate detection of these nodes is essential for imaging of lymph drainage from a tumor bed that may comprise cancer cells through the initial tumor spreading via the lymphatic's. Thus, finding a sentinel node free from cancer strongly proves that the tumor has not spread yet. Subcutaneous administration of highly stable ^99m^Tc-GNP-mannose in rats validated its radiochemical purity. A noticeable lymph node uptake and minimal kidney accumulation of this radio-nanoconjugate was monitored by *in vivo* micro-SPECT/CT imaging which could be a sign of target-specific ability for SLN detection.^[@R64]^ Su *et al*. (2015) has formulated a multifunctional ^125^I labeled cRGD-GNPs agent as tumor-targeted radio sensitizer. Radioactive iodine-125 (^125^I) was used for labeling a hybrid nanosized cyclic Arg-Gly-Asp conjugated GNPs (cRGD-GNPs). The ^125^I radionuclide was introduced in the form of radio sensitizer to serves as both therapeutic factor and radiotracer for *in vivo* tracking of GNPs. Therapeutic effects of ^125^I like acute apoptosis was detected in NCI-H446 tumor-bearing mice via ^99m^Tc-Annexin V SPECT, while a valuable radio sensitized RT-induced volume loss as long-term influence proved high radiotherapy and targeting efficiency of ^125^I-cRGD-GNPs *in vivo.* SPECT/CT imaging of cRGD-GNPs showed a high uptake of this nanoprope by tumor tissues (the peak target/non-target value) which offers the importance of method in developing radionuclide-labeled radio sensitizer for improved radiotherapy.^[@R119]^

Conclusion {#s5}
==========

The development of nanoscaled radiopharmaceuticals by amalgamating multiple properties in the field of molecular imaging and therapy has gained much attention in the last decade. Direct comparison and validation are achievable by applying these dual-labeled target-guided imaging nanoprobes. In fact, modifying various potential NPs and/or biomolecules can provide an opportunity for fabricating multifunctional NSs that are used in hybrid imaging platforms. The multifunctional radiolabeled NSs combine imaging and therapeutic agents in one single preparation that can be subsequently used for specific targeting of the diseased site passively or actively. All contrast agents in clinically imaging modalities are formulated to absorb definite signal much stronger than the adjacent tissues. Inorganic and organic NPs possess specific plasmonic, magnetic, and optical aspects, and GNPs for instance, produce imaging contrast (optical imaging) and have thermo ablative features. The receptor-specific radiopharmaceuticals have significant potential to be used for targeted radiotherapy. High uptake of therapeutic NPs by organs such as the RES is a result of the NPs colloidal nature, which could be limited by injection of these NPs through intra-tumoral administration or into a selective artery. In addition, the surface modification with PEG results in developing of highly stable NPs for biomedical imaging with low RES uptake and long blood circulation time. High concentration of NPs in the tumor can reduce the systemic side effects of the administered NPs, which can be achieved by passive and active targeting mechanisms. Several iron oxide and GNPs have already shown great potential in multifunctional regimen for imaging and disease therapy. Conjugated radio-labeled GNPs could potentially be a radiotherapeutic NS at cellular level. The rapid development of producing the multifunctional radiolabeled NSs with the capability of detection, imaging, and treating of diseases is an ongoing filed in utilizing the best choice to resolve therapeutic problems. The great challenges in the translation of multifunctional NSs seem to be the development of NSs with high *in vivo* stability, immune compatibility, and low/no toxicity. In conclusion, we articulated that the functionalized GNPs and MNPs have great potential in various imaging and/or therapeutic applications. With appropriate surface modification and functionalization, multimodal GNPs and MNPs can be used for target-guided imaging, photothermal therapy, photodynamic therapy of different malignancies, and also deliver drugs/genes to the diseased cells/tissue through both passive and active targeting mechanisms.
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Review Highlights {#s9}
=================

What is current knowledge?√ The application of functionalized nanoparticles (NPs) for targeted imaging and therapy (so-called diapeutics/ theranostics) of various malignancies has rapidly been advanced.√ These multimodal nanosystems (NSs) function as sensitive seamless nanoprobes and are used in molecular imaging (PET, SPECT, CT, MRI), photothermal therapy and drug delivery.√ PET, SPECT and their hybrid imaging modality are valuable technologies that provide great diagnosis capacities in clinic.What is new here?√ Radiolabeled NSs can be engineered as all-in-one multimodal systems to combine imaging, with photothermal/ photodynamic therapy while delivering the loaded drugs or genes to the targeted cells/tissues.√ These NSs can be designed to become stimuli-responsive and liberate drugs/genes on-demand.
